Miami Cancer Institute

Miami Cancer Institute to Present Latest Research at 2024 San Antonio Breast Cancer Symposium

December 4, 2024

MIAMI, FL & SAN ANTONIO, TX – December 4, 2025 – Researchers from Miami Cancer Institute, part of Baptist Health South Florida, will present 11 posters and moderate one general session at this year’s San Antonio Breast Cancer Symposium (SABCS), hosted December 10-13, 2024, at the Henry B. Gonzalez Convention Center. Miami Cancer Institute researchers will present the latest advances in HER2-low metastatic breast cancer, metaplastic breast cancer, as well as chemotherapy in elderly breast cancer patients, among others.

“I am very pleased with the quality of the research that my colleagues and I will be discussing at this year’s San Antonio Breast Cancer Symposium. We will be highlighting an ongoing prospective trial we are leading, which is one of the first trials that will hopefully shed some light on the important area of sequencing antibody drug conjugates in metastatic breast cancer,” said Reshma L. Mahtani, D.O., chief of breast medical oncology at Miami Cancer Institute. “Additionally, we will be presenting on a subgroup analysis of genomic results from a larger multicenter cohort study of HER2-low metastatic breast cancer, a retrospective analysis of the association between body composition measures and relative dose intensity of (neo)adjuvant chemotherapy in elderly breast cancer patients, and a retrospective U.S. electronic health records study on HER2+-early breast cancer treatment and outcomes by risk of recurrence, among numerous others. These advances, together with many others shared at the symposium, are a true source of hope for patients affected by breast cancer in the U.S. and across the globe.”

Miami Cancer Institute researchers led the following researchers presented at SABCS 2024:

Poster Presentations

Wednesday, December 11, 2024

Hidden challenge: atypical ductal hyperplasia in vulvar ectopic breast tissue

Presenter: Ana Cristina Sandoval Leon, M.D.

Time: 12:00 p.m. – 2:00 p.m. CT

Location: Halls 2-3

Number: P1-10-18

PreciseBreast, an AI-enabled digital test predicting breast cancer recurrence is equivalent with Oncotype in an observational, retrospective study of patients from Baptist Health

Presenter: Reshma Mahtani, D.O.

Location: Halls 2-3

Number: P2-06-22

Thursday, December 12, 2024

A multicenter retrospective review of a large cohort of patients with metaplastic breast cancer

Presenter: Naomi Grace Dempsey, M.D.

Time: 12:00 p.m. – 2:00 p.m. CT

Location: Halls 2-3

Number: P3-03-20

Multicenter retrospective cohort study of the sequential use of antibody drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC): a subgroup analysis of next generation sequencing results

Presenter: Reshma Mahtani, D.O.

Time: 12:00 p.m. – 2:00 p.m. CT

Location: Halls 2-3

Number: P3-05-21

Post-Mastectomy Proton Therapy Imparts Increased Risk of Capsular Contracture in Reconstructed Breast Cancer Patients

Presenter: Mehmet Murat Zerey, M.D.

Location: Room 221ABC

Number: PS6-03

SERIES: sequencing sacituzumab govitecan (SG) after trastuzumab deruxtecan (T-DXd) in ER+/HER2-low metastatic breast cancer

Presenter: Reshma Mahtani, D.O.

Time: 12:00 p.m. – 2:00 p.m. CT

Location: Halls 2-3

Number: P3-10-26

The AmeliaTM-1 study: A phase 1b/2 study assessing the safety and efficacy of evexomostat (SDX-7320) plus a PI3K/Akt inhibitor and fulvestrant in patients with advanced HR+/Her2- breast cancer

Presenter: Reshma Mahtani, D.O.

Time: 12:00 p.m. – 2:00 p.m. CT

Location: Halls 2-3

Number: P3-08-18

Friday, December 13, 2024

A retrospective analysis of the association between body composition measures and relative dose intensity of (neo)adjuvant chemotherapy for elderly breast cancer patients

Presenter: Naomi Grace Dempsey, M.D.

Time: 12:00 p.m. – 2:00 p.m. CT

Location: Halls 2-3

Number: P5-10-28

HER2+ early breast cancer treatment and outcomes by risk of recurrence: a retrospective U.S. electronic health records study

Presenter: Reshma Mahtani, D.O.

Time: 12:00 p.m. – 2:00 p.m. CT

Location: Halls 2-3

Number: P5-07-24

Impact of socioeconomic factors on stage of diagnosis and mortality among breast cancer patients: an NCDB analysis

Presenter: Ana Cristina Sandoval Leon, M.D.

Time: 12:00 p.m. – 2:00 p.m. CT

Location: Halls 2-3

Number: P5-02-15

Multi-institutional quality improvement on HER2-positive and HER2-low metastatic breast cancer

Presenter: Reshma Mahtani, D.O.

Time: 12:00 p.m. – 2:00 p.m. CT

Location: Halls 2-3

Number: P5-05-27

General Sessions

Wednesday, December 11, 2024

General Session 1

Moderator: Reshma Mahtani, D.O.

Time: 9:15 a.m. – 11:30 a.m. CT

Location: Hall 1

For updates from the San Antonio Breast Cancer Symposium 2024, look for #SABCS2024 on social media and follow Miami Cancer Institute on X (Twitter) at @MiamiCancerInst.

About Miami Cancer Institute

Miami Cancer Institute brings to South Florida access to personalized clinical treatments and comprehensive support services delivered with unparalleled compassion. No other cancer program in the region has the combination of cancer-fighting expertise and advanced technology—including the first proton therapy center in South Florida, Latin America and the Caribbean, and one of the only radiation oncology programs in the world with each of the newest radiation therapies in one place—to diagnose and deliver precise cancer treatments that achieve the best outcomes and improve the lives of cancer patients. The Institute offers an impressive roster of established community oncologists and renowned experts, clinical researchers and genomic scientists recruited from the nation’s top cancer centers. Selected as Florida’s only member of the Memorial Sloan Kettering Cancer (MSK) Alliance, Miami Cancer Institute is part of a meaningful clinical collaboration that affords patients in South Florida access to innovative treatments and ensures that the standards of care developed by their multidisciplinary disease management teams match those at MSK. For more information, please visit https://baptisthealth.net/services/cancer-care/miami-cancer-institute.

Miami Cancer Institute is part of Baptist Health Cancer Care, the largest cancer program in South Florida, with locations from the Florida Keys to the Palm Beaches.

###

Language Preference / Preferencia de idioma

I want to see the site in English

Continue In English

Quiero ver el sitio en Español

Continuar en español